Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Endocrine therapy treatment radiosensitizes ER+ breast cancer

Corey Speers • 9 Dec 2021
SABCS 2021
Breast Cancer

Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, outlines the use of endocrine therapy treatment, which has been investigated in preclinical models, to radiosensistize estrogen receptor (ER)-positive breast cancers. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Corey Speers

1:27
16-gene signature identifies early-stage invasive breast cancer patients who may omit radiotherapy
Corey Speers • 9 Dec 2021
1:12
Impact of genomic testing on treatment decision-making in breast cancer
Corey Speers • 9 Dec 2021
1:18
Predicted sensitivity to ET (SET2,3 index): results of an analysis of the SWOG S8814 trial
Corey Speers • 9 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals